Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The group's high margin levels account for strong profits.
  • With a P/E ratio at 14.61 for the current year and 12.63 for next year, earnings multiples are highly attractive compared with competitors.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 60.68 EUR
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
IPSEN1.27%7 901
JOHNSON & JOHNSON-1.28%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER INC.0.30%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049
ABBVIE INC.18.47%185 181
NOVO NORDISK A/S8.43%155 954
BRISTOL-MYERS SQUIBB COMPAN..-1.78%142 477
ASTRAZENECA PLC2.14%135 908
ELI LILLY AND COMPANY12.18%133 666
AMGEN INC.-6.74%130 877
SANOFI-4.92%127 996
GLAXOSMITHKLINE PLC-22.23%91 797
CHUGAI PHARMACEUTICAL CO., ..42.95%76 661
DAIICHI SANKYO COMPANY, LIM..56.60%72 682
More Results
Financials
Sales 2020 2 654 M 3 164 M 3 164 M
Net income 2020 461 M 550 M 550 M
Net Debt 2020 717 M 855 M 855 M
P/E ratio 2020 14,6x
Yield 2020 1,27%
Capitalization 6 678 M 7 982 M 7 963 M
EV / Sales 2020 2,79x
EV / Sales 2021 2,46x
Nbr of Employees 5 807
Free-Float 42,0%
Upcoming event on IPSEN
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes